BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $861,851 | +54.1% | 32,683 | +0.5% | 0.00% | +100.0% |
| Q2 2023 | $559,224 | -5.2% | 32,513 | -8.6% | 0.00% | 0.0% |
| Q1 2023 | $589,966 | +117.6% | 35,583 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $271,142 | -35.1% | 35,583 | -15.5% | 0.00% | 0.0% |
| Q3 2022 | $418,000 | +9.4% | 42,093 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $382,000 | -10.5% | 42,093 | +0.0% | 0.00% | 0.0% |
| Q1 2022 | $427,000 | -39.2% | 42,083 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $702,000 | -64.4% | 42,083 | -0.0% | 0.00% | -75.0% |
| Q3 2021 | $1,972,000 | -22.4% | 42,084 | +0.9% | 0.00% | -20.0% |
| Q2 2021 | $2,542,000 | +14.9% | 41,704 | +16.1% | 0.01% | +25.0% |
| Q1 2021 | $2,213,000 | -2.9% | 35,922 | +12.0% | 0.00% | -20.0% |
| Q4 2020 | $2,280,000 | +78.8% | 32,060 | -5.6% | 0.01% | +66.7% |
| Q3 2020 | $1,275,000 | +27.5% | 33,970 | +10.7% | 0.00% | +50.0% |
| Q2 2020 | $1,000,000 | +123.7% | 30,680 | +99.2% | 0.00% | +100.0% |
| Q1 2020 | $447,000 | – | 15,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |